| Revenue growth | 29% YoY growth in Q1 FY27. |
|---|---|
| Margins | Gross margins expanded 330 bps YoY to 62.7%. |
| Order book | Over 125 active projects in CDMO pipeline. |
| Demand visibility | Healthy order book in Affordable Medicines and CDMO pipeline. |
| Management confidence | High, citing strong CDMO momentum and manufacturing expansion. |
Growth
Revenue grew 29% YoY to ₹2,026 Cr; Net Profit surged 126% YoY to ₹368 Cr. CDMO small molecules revenue increased 69% YoY.
Outlook
Cumulative FY22-27 CAPEX target set at ₹4,700+ Cr. Fermentation facility (Vizag) commissioning expected by 3QFY27; ADC facility qualification by end 2027.
Risks
Global supply chain challenges persist. Bio segment revenue saw a 46% QoQ decline despite YoY growth.
Last quarter's promises, checked
Delivered
- Guided FY26 EBITDA margins 26.8% → delivered 26.8% (= BEAT)
- Guided FY26 Revenue ~₹6,800 Cr → delivered ₹6,813 Cr (= BEAT)
- Guided ARV Revenue quantum constant ~₹2,800 Cr → delivered ₹2,800 Cr (= BEAT)
Partly delivered
- Guided FY27 CDMO growth → delivered 67% YoY in Q1 (Partial: momentum high but FY target in progress)
Investor Presentation filed with BSE, NSE: LAURUSLABS. Summary written with AI assistance from the document.
Laurus Labs Ltd: key numbers
- Share price
- ₹2,007.00
- Market cap
- ₹1,08,441 Cr
- Revenue (annual)
- ₹6,813 Cr
- Net profit (annual)
- ₹888.8 Cr
- P/E (TTM)
- 99.2×Sector 50.4×
- Promoter holding
- 27.47%-0.02% QoQ
- FII holding
- 28.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Laurus Labs Ltd
All →Laurus Labs Investor Presentation: Key Takeaways
Laurus Labs delivered record Q1FY27 revenue of ₹2,026 Cr, a 29% YoY increase, driven by robust CDMO growth. EBITDA margins expanded 700 bps YoY to 31.8% on favorable mix.
Laurus Labs Earnings Call Transcript: Key Takeaways
Laurus Labs delivered record quarterly revenue and EBITDA margins, driven by strong CDMO commercial supplies and recovery in the affordable medicine portfolio.
- Call
- Guides 50% growth
Laurus Labs Q1 FY27 Results: Net Profit ₹362.1 Cr, Up 123.9% YoY
Laurus Labs Ltd reported revenue from operations of ₹2,026 Cr (+29.1% YoY) and net profit of ₹362.1 Cr (+123.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹362.1 Cr · +123.9% YoY
Laurus Labs Earnings Call: Key Takeaways
Laurus Labs delivered strong Q4 FY26 results with 23% annual revenue growth and significant EBITDA margin expansion to 26.8%, driven by a transforming CDMO business and generic portfolio ramp-up.
Laurus Labs Earnings Call: Key Takeaways
Laurus Labs delivered a robust 23% revenue growth in FY26, pivotally shifting its mix toward CDMO which now accounts for 30% of sales while maintaining ARV leadership.
Laurus Labs Earnings Call: Key Takeaways
Laurus Labs delivered record FY26 results with Revenue up 23% and Net Profit surging 148%, driven by a significant 36% jump in CDMO and improved operating leverage.